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Germline mutations distributed across the PTEN tumor-suppressor gene have been found to result in a wide
spectrum of phenotypic features. Originally shown to be a major susceptibility gene for both Cowden syndrome
(CS), which is characterized by multiple hamartomas and an increased risk of breast, thyroid, and endometrial
cancers, and Bannayan-Riley-Ruvalcaba syndrome, which is characterized by lipomatosis, macrocephaly, and
speckled penis, the PTEN hamartoma tumor syndrome spectrum has broadened to include Proteus syndrome
and Proteus-like syndromes. Exon 5, which encodes the core motif, is a hotspot for mutations likely due to the
biology of the protein. PTEN is a major lipid 3-phosphatase, which signals down the PI3 kinase/AKT pro-
apoptotic pathway. Furthermore, PTEN is a protein phosphatase, with the ability to dephosphorylate both serine
and threonine residues. The protein-phosphatase activity has also been shown to regulate various cell-survival
pathways, such as the mitogen-activated kinase (MAPK) pathway. Although it is well established that PTEN’s
lipid-phosphatase activity, via the PI3K/AKT pathway, mediates growth suppression, there is accumulating ev-
idence that the protein-phosphatase/MAPK pathway is equally important in the mediation of growth arrest and
other crucial cellular functions.
Introduction
Prior to 1996, when the susceptibility gene for Cow-
den syndrome (CS [MIM 158350]) was mapped to
10q22-q23 (Nelen et al. 1996), the molecular bases
of the inherited hamartoma-tumor syndromes were
obscure. CS is an autosomal dominant disorder that
is characterized by multiple hamartomas that affect
derivatives of all three germ layers and by a risk of
breast, thyroid, and endometrial neoplasias (Appen-
dix A) (Eng 2000). Germline mutations in PTEN/
MMAC1/TEP1 (MIM 601728), a tumor-suppressor
gene located on 10q23, have since been found in 80%
of probands with CS (Liaw et al. 1997; Marsh et al.
1998b). PTEN encodes a lipid dual-specificity phos-
phatase and is the major 3-phosphatase in the phos-
phoinositol-3-kinase (PI3K)/AKT pro-apoptotic path-
way (Li and Sun 1997; Li et al. 1997; Steck et al.
1997; Maehama and Dixon 1998; Stambolic et al.
1998). This represents the first phosphatase gene that
has been implicated in the etiology of an inherited
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cancer syndrome. Subsequently, the clinical spectrum
of disorders that are associated with germline PTEN
mutations has expanded to include seemingly dispa-
rate syndromes.
Identification of PTEN
PTEN was first identified in 1997 by three indepen-
dent groups, each of which had slightly different strat-
egies. Two groups used positional-cloning approaches
to map this gene to 10q23 (Li et al. 1997; Steck et
al. 1997); sequence analysis showed a large region of
homology to chicken tensin, bovine auxilin, and a
protein tyrosine-phosphatase domain, from which the
name “PTEN” was coined (for phosphatase and ten-
sin homolog, deleted on chromosome 10 [ten]). A
third group (Li and Sun 1997) identified PTEN by
searching for genes with its biochemical properties.
Li and Sun searched for novel human protein tyrosine
phosphatases by using two different methods (Li and
Sun 1997). By searching GenBank for entries that con-
tain phosphatase motifs and using a PCR-based ap-
proach to screen a human cDNA library, they iden-
tified TEP1 (transforming growth factor [TGF]–
regulated and epithelial cell-enriched phosphatase),
which was also shown to be identical to PTEN. TEP1
was shown to dephosphorylate an in vitro substrate
for tyrosine phosphatases (phosphotyrosyl-RCML).
Furthermore, Li and Sun demonstrated that when the
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essential cysteine in the tyrosine-phosphatase motif
was mutated, a mutation that occurs in CS, the phos-
phatase activity was abolished (Li and Sun 1997).
CS
CS exhibits variable expressivity, which makes the diag-
nosis of CS and the accurate measurement of its incidence
a challenge. Before the identification of the susceptibility
gene, the incidence was thought to be 1/1,000,000 (Nelen
et al. 1996). However, after identification of PTEN as the
gene for CS (Liaw et al. 1997), a molecular-based study
revealed the incidence to be 1/200,000 (Nelen et al.
1997, 1999), although this too is likely to be an under-
estimate. Because CS is underdiagnosed, a true count of
the proportion of isolated cases (defined as having no
obvious family history) and familial cases (defined as hav-
ing two or more related affected individuals) cannot be
performed. From the literature and the experience of ma-
jor CS centers in the world, the majority of CS cases
appear to be isolated. As a broad estimate, ∼10%–50%
of CS cases are familial (Marsh et al. 1999).
Because of the lack of uniform diagnostic criteria for
CS prior to 1995, the International Cowden Consor-
tium arrived at a set of consensus operational diagnostic
criteria culled from published data and expert opinion
(Nelen et al. 1996; Eng 1998). This consortium repre-
sented a group of centers, mainly in North America and
Europe, that were interested in systematically studying
this syndrome to localize the susceptibility gene. These
diagnostic criteria have been revised recently, in the con-
text of new data, and are reflected in the practice guide-
lines of the U.S.-based National Comprehensive Cancer
Network (NCCN) Genetics/High Risk Panel (Appendix
B) (NCCN 1999; Eng 2000).
More than 90% of individuals affected with CS are
believed to manifest a phenotype by the age of 20
years (Nelen et al. 1996; Eng 2000). By the end of
the 3d decade of life (i.e., at 29 years of age), 99%
of affected individuals are believed to have developed
at least the mucocutaneous signs of the syndrome,
although any of the other clinical features could also
be present (Appendixes A and B). The most com-
monly reported manifestations are mucocutaneous le-
sions, thyroid abnormalities, fibrocystic disease, and
carcinoma of the breast, multiple, early-onset uterine
leiomyoma, and macrocephaly (specifically, megalen-
cephaly) (Appendix A) (Starink et al. 1986; Hanssen
and Fryns 1995; Mallory 1995; Longy and Lacombe
1996; Eng 2000). Mucocutaneous trichilemmomas
and papillomatous papules are considered diagnostic
of the syndrome (Appendix B).
The two most well-documented component malig-
nancies of CS are carcinomas of the breast and epithelial
thyroid gland (Starink et al. 1986). In women with CS,
lifetime risks of breast cancer are estimated to be
25%–50% (Starink et al. 1986; Hanssen and Fryns
1995; Longy and Lacombe 1996; Eng 1997) in contrast
to the 11% in the general population. The mean age at
diagnosis is likely 10 years earlier than that in the gen-
eral population, at ∼38–48 years of age, with a range
of 14–65 years of age (Starink et al. 1986; Longy and
Lacombe 1996). Until genotype-phenotype analyses
were performed with the discovery of the susceptibility
gene, it was thought that male breast cancer was not a
component of CS. However, male breast cancer does
occur in PTEN-mutation–positive CS, but with un-
known frequency (Marsh et al. 1998b; Fackenthal et al.
2001). The lifetime risk of epithelial thyroid cancer can
be as high as 10% in males and females with CS. It is
unclear if the age at onset is truly earlier than that of
the general population. Histologically, CS-associated
thyroid cancer is predominantly follicular carcinoma,
although papillary histology has also been rarely ob-
served (Starink et al. 1986; Hanssen and Fryns 1995;
Longy and Lacombe 1996; C. Eng, unpublished data).
After identification of PTEN as the susceptibility gene,
preliminary data suggested that endometrial carcinoma
is a component cancer of CS (Marsh et al. 1998a; De
Vivo et al. 2000; Eng 2000). Its frequency in mutation
carriers is as yet unknown.
Germline PTEN Mutations Cause CS
Germline mutations in PTEN, have been found in CS
(Liaw et al. 1997; Lynch et al. 1997; Nelen et al. 1997,
1999; Tsou et al. 1997; Marsh et al. 1998b). Although
the original linkage study mapped CS to 10q22-q23
without genetic heterogeneity (Nelen et al. 1996), one
subsequent study suggested that rare locus heterogeneity
may exist (Tsou et al. 1997). It is unclear if BMPR1A,
which is on 10q22 and encodes a bone morphogenic
protein receptor belonging to the TGF-b–receptor su-
perfamily, is a susceptibility gene for juvenile polyposis
syndrome (Eng 2001; Howe et al. 2001), is also a rare
susceptibility gene for CS (Zhou et al. 2001b).MINPP1,
another gene that maps to 10q23 upstream from PTEN
and that encodes a phosphatase, has been excluded as
a locus for CS (Dahia et al. 2000).
When CS is strictly defined by the operational diag-
nostic criteria of the International Cowden Consortium,
80% have been found to harbor germline PTEN mu-
tations (Marsh et al. 1998b). Approximately two-thirds
of these mutations were found in exons 5, 7, and 8 (fig.
1 and table 1). Approximately 40% of all CS germline
mutations are located in exon 5, although exon 5 rep-
resents only 20% of the coding sequence. Genotype-
phenotype analyses revealed an association between the
presence of germline mutations and malignant breast
disease (Marsh et al. 1998b). In other words, more ma-
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Figure 1 Germline PTEN mutations in CS, BRRS, PS, and Proteus-like syndromes
lignant breast disease occurred in the 80% of families
with CS diagnosed by the International Cowden Con-
sortium criteria and who were mutation positive, com-
pared to the 20% of families who also met International
Cowden Consortium criteria but were mutation nega-
tive. In addition, missense mutations and those within
and 5′ to the phosphatase core motif appear to be as-
sociated with involvement of five or more organs, a
surrogate phenotype for severity of disease (Marsh et
al. 1998b). Another group examined families for germ-
line PTEN mutations and found mutations in only 13
(∼50%) probands (Nelen et al. 1999). They could not
find any clear genotype-phenotype associations, almost
certainly due to their small sample size and consequent
lack of statistical power. The differences in mutation
frequency between the studies by Marsh et al. (1998b)
and Nelen et al. (1999) include a decreased stringency
of ascertainment by the International Cowden Consor-
tium criteria and, perhaps, small sample size in the latter
study.
Clinical Spectrum of PTEN-Defined Syndromes:
The Concept of the PTEN Hamartoma-Tumor
Syndrome (PHTS)
Bannayan-Riley-Ruvalcaba Syndrome (BRRS)
Germline PTEN mutations in families with BRRS
(MIM 153480), characterized by macrocephaly, lipom-
atosis, hemangiomatosis and speckled penis (Gorlin et
al. 1992), have also been found (fig. 1) (Marsh et al.
1997a). Thus, at least a subset of patients with BRRS
and CS may be considered allelic. In contrast to patients
with CS, 60% of patients with BRRS were found to have
germline PTEN mutations (Marsh et al. 1999). These
mutations included one with a cytogenetically detectable
deletion of 10q23, encompassing PTEN, and a trans-
location involving 10q23 (Arch et al. 1997; Ahmed et
al. 1999; Marsh et al. 1999). The mutational spectra of
BRRS and CS seem to overlap, lending formal proof
that CS and BRRS are allelic (Marsh et al. 1999). Thus,
it has been suggested that syndromes that are charac-
terized by the presence of germlinePTENmutationsmay
be grouped by molecular definition and referred to as
the “PHTSs” (Marsh et al. 1999).
Genotype-phenotype association analyses revealed
several correlations in BRRS (Marsh et al. 1999). The
presence of germline PTEN mutations was found to be
correlated with the presence of breast tumors, the pres-
ence of breast fibroadenomas, and lipomatosis. In other
words, there was a higher frequency of breast tumors,
fibroadenomas, and lipomas among the group of pa-
tients with BRRS, all of whom met published diagnostic
criteria (Gorlin et al. 1992) and were found to be mu-
tation positive, compared to the 40% of patients with
BRRS, who also met diagnostic criteria but were mu-
tation negative. In this analysis, there were nine families
with clinical overlap of CS and BRRS; eight of these nine
families were found to harbor germline PTENmutations
(Marsh et al. 1999). This high frequency of mutation
positivity among families with overlap continues to hold
true, since such families continue to be accrued and sub-
jected to mutation analysis (Celebi et al. 1999; Wanner
et al. 2001; X. P. Zhou and C. Eng, unpublished data).
One report suggested that germline PTEN mutations
occur only in familial BRRS but not isolated (i.e., non-
familial) BRRS (Carethers et al. 1998). However, this
finding has not held true in multiple other studies (Arch
et al. 1997; Longy et al. 1998; Zori et al. 1998; Marsh
et al. 1999). In the largest single series of patients with
isolated BRRS, 7 of 16 unrelated probands with isolated
BRRS were found to have germline intragenic PTEN
mutations (Marsh et al. 1999). If we also considered
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Table 1
Missense Mutations in PTEN Tested for Lipid Phosphatase Activity
Mutation Domain
Phosphatase
Activitya
S10N Phosphatase Full
Y16C Phosphatase Null
G20E Phosphatase Partialb
Y27S Phosphatase Null
L42R Phosphatase Full
H61R Phosphatase Null
Y68R Phosphatase Null
C71Y Phosphatase Null
H93Y Phosphatase/active core Null
C105F Phosphatase Null
D107Y Phosphatase Null
L112P Phosphatase Null
L112R Phosphatase Null
A121 Phosphatase Null
C124R Phosphatase/active core Null
G129R Phosphatase/active core Null
G129E Phosphatase/active corec Null
R130G Phosphatase/active core Null
R130L Phosphatase/active core Null
R130Q Phosphatase/active core Null
V133I Phosphatase Null
M134L Phosphatase Partialb
C136 Phosphatase Null
Y155 Phosphatase Null
G165R Phosphatase/active core Null
S170N Phosphatase Null
S170R Phosphatase Null
R173C Phosphatase Null
R173H Phosphatase Null
R173P Phosphatase Null
Y174N Phosphatase Null
S227F C2 Partialb
G251C C2 Null
K289E C2 Full
D331G C2 Partial
F341V C2 Null
K342N C2 Partialb
V343E C2 Null
L345Q C2 Null
F347L C2 Partial
V369 C terminus Full
T401 C terminus Full
NOTE.—Adapted from Han et al. (2000).
a Lipid-phosphatase activity toward inositol-1,3,4,5-tetraphosphate.
b Full-lipid-phosphatase activity to PIP3.
c Protein-phosphatase active.
large rearrangements, 9 of 18 patients with isolated
BRRS harbored a germline PTEN alteration. This fre-
quency of mutation-positive cases is not significantly dif-
ferent from that obtained for familial BRRS.
Currently, it is unclear if the 40% of BRRS without
germline PTEN mutations have large rearrangements
affecting PTEN or if genes other than PTEN may also
be responsible for BRRS. MINPP1 has also been ex-
cluded as a susceptibility gene for PTEN-mutation–
negative BRRS (Dahia et al. 2000).
Proteus Syndrome (PS) and Proteus-like Syndromes
Although PS (MIM 176920) had always been consid-
ered part of the genetic differential diagnosis of CS, it
was often discarded as being part of PHTS. The mosaic
distribution of affected tissues in PS and its sporadic
occurrence strongly suggested either somatic mutation
or germline mosaic mutation as its etiology. Interestingly,
during the ascertainment of probands with the minimal
clinical features of hamartomas, lipomas and over-
growth, an individual with a Proteus-like syndrome was
found to carry a germline PTEN R335X mutation and
a second-hit germline mosaic R130X mutation in his
affected tissues (Zhou et al. 2000). This individual was
born of normal parents and had marked hemihypertro-
phy, macrocephaly, epidermoid nevi, lipomas, and pro-
gressively worsening arterioventricular malformations,
features that are reminiscent of PS but do not meet the
full published criteria for the clinical diagnosis of PS
(Biesecker et al. 1999). This individual with a Proteus-
like syndrome also did not meet the criteria for the di-
agnosis of either CS or classic BRRS.
Given these observations, a series of nine unrelated pa-
tients with isolated PS and five individuals with Proteus-
like syndromes were analyzed for the presence of germline
PTEN mutations (fig. 1) (Zhou et al. 2001a). Of the nine
patients with classic PS who met the published clinical
criteria (Biesecker et al. 1999), two were found to have
germline PTEN mutations, W211R and C211X, neither
of which have previously been found in CS or BRRS
(Zhou et al. 2001a). Three of the five individuals with a
Proteus-like syndrome were also found to have germline
PTEN mutations. Interestingly, R335X, which has also
been found in CS and BRRS, was found in the germline
of two of these individuals. The third, M35T, is, thus far,
unique. There is at least one other small series of indi-
viduals with PS that was examined for the presence of
PTEN mutations (Barker et al. 2001). Among eight in-
dividuals with PS, nomutations were found. This negative
result is almost certainly due to small sample size and/or
may be secondary to the mutation-scanning method cho-
sen, conformation-specific gel electrophoresis, which has
been shown to be relatively insensitive even in the best of
hands (Eng et al. 2001). Together, these data suggest that
subsets of both PS and Proteus-like syndromes may be
considered PHTS. It is also clear that other susceptibility
genes will be found for PS and Proteus-like syndromes.
Although PTEN-mutation–positive CS, BRRS, PS,
and Proteus-like syndromes are considered in the PHTS
continuum, the phenotypes associated with the same
mutation can vary quite remarkably (Appendix A). This
is particularly pronounced for the hotspot mutations on
CpG islands, R233X, R235X, and R335X.
Waite and Eng: Features of PTEN 833
Other Clinical Syndromes?
Germline PTEN mutations have been uncovered in
a single case of isolated hydrocephaly with VATER
association (Reardon et al. 2001) and an individual
with megalencephaly with autistic features (Dasouki
et al. 2001). VATER association comprises vertebral
and anal malformations, tracheoesophageal atresia,
and radial and renal malformations. VATER associ-
ated with hydrocephaly is a distinct entity from VA-
TER association alone, and, unlike VATER, familial
cases have been reported (Iafolla et al. 1991; De-
vriendt et al. 1995; reviewed in Reardon et al. 2001).
In the latter case, it is unclear if the autistic features
are part of PHTS or if it is only the megalencephaly
that is germane. Both of these types of clinical pres-
entations are extremely rare, and further investigation
is required to determine if these clinical syndromes
are also prominent members of PHTS.
Clinical Syndromes That Are Not PHTS
The molecular classification of PHTS is important in two
ways. First, the broadening phenotypic spectrum of
PHTS yields clues to fundamental insights into the struc-
ture-function relationship of PTEN. Second, the PHTS
molecular classification of clinical syndromes is impor-
tant from a clinical management point of view. Geno-
type-phenotype analyses have suggested that the pres-
ence of germline mutations, in CS or BRRS, is associated
with cancer, at least breast cancer (Marsh et al. 1998b,
1999). Thus, a conservative clinician would recommend
cancer surveillance for all individuals with PHTS, as is
advocated for classic CS, irrespective of their clinical
diagnosis (Eng 2000).
There are several inherited hamartoma-tumor syn-
dromes that do not belong to PHTS. Peutz-Jeghers syn-
drome (PJS [MIM 175200]) is an autosomal dominant
inherited cancer syndrome characterized by gastroin-
testinal hamartomatous polyposis, peroral pigmenta-
tion, and a risk of gastrointestinal and breast cancers.
Its susceptibility gene isLKB1/STK11, on 19p, encoding
a nuclear serine threonine kinase (Hemminki et al.
1997, 1998; Jenne et al. 1998). PTEN has been ex-
cluded as a locus in PJS (D. J. Marsh and C. Eng, un-
published data).
Juvenile polyposis syndrome (JPS [MIM 174900]) is
a clinical diagnosis of exclusion, and there has been
some confusion whether JPS is a PHTS (Eng and Ji
1998). JPS is an autosomal dominant disorder charac-
terized by gastrointestinal hamartomatous polyps (“ju-
venile polyps”) and a risk of gastrointestinal cancers.
Initial confusion stemmed from a paper that described
germline PTEN mutations in two individuals who had
been reported to have JPS (Olschwang et al. 1998). It
became clear, however, that the insufficiently detailed
clinical descriptions that were provided for these pa-
tients strongly suggested that these individuals had CS
or BRRS (Eng and Ji 1998). Similarly, the title of one
report referred to germline mutations in individuals
with JPS, but it was obvious, from the text, that all of
these individuals had CS (Lynch et al. 1997). Even re-
cently, a small study reported that PTEN may be a rare
JPS-susceptibility gene (Huang et al. 2000), but, again,
insufficient clinical detail was given in this report to
determine if these individuals had features of either CS
or BRRS. At least one series systematically examined
this issue. The first was a single hospital-based series
that looked for germline PTEN mutations in diagnoses
of JPS (Kurose et al. 1999). In this series, one individual
was found to harbor a germline PTENmutation. When
that individual was recalled for thorough examination,
classic cutaneous features of CS were found (Kurose et
al. 1999). PTEN was formally excluded as a JPS-sus-
ceptibility gene (Marsh et al. 1997b), and we now know
that germline mutations in MADH4 on 18q and
BMPR1A on 10q21-q22 account for 40%–60% of JPS
(Howe et al. 1998a, 1998b, 2001; Zhou et al. 2001b).
Overall, the data to date suggest that JPS is not a
PHTS. However, the discovery of a germline PTENmu-
tation in an individual considered to have JPS should
raise the suspicion that the clinical diagnosis is incorrect
and that such an individual be medically managed in
the same manner as all patients with PHTS.
Murine Models
Animal models of human disease are helpful when they
faithfully recapitulate the human disease and/or when
they can be utilized for fundamental research that can
elucidate the biology of the gene in question. Three dif-
ferent groups have generated Pten-knockout mice. All
three groups targeted exon 5 in the targeting construct
(Di Cristofano et al. 1998; Suzuki et al. 1998; Podsy-
panina et al. 1999), and two of these groups also deleted
extra exons (i.e., exons 3–5 [Suzuki et al. 1998] and
exons 4 and 5 [Di Cristofano et al. 1998]). The third
group targeted a frameshift mutation within the phos-
phatase motif (Podsypanina et al. 1999). These groups
all reported that homozygous knockout of Ptenwas em-
bryonic lethal within a range of embryonic days 6.5–
9.5. Beyond this, however, the groups observed varied
phenotypes in the heterozygous mice. Few features of
CS or BRRS have been described in these models, al-
though each model contains features that are reminiscent
of these disorders. For example, one model is charac-
terized by abnormal development of the three germinal
layers, as well as skin hyperkeratosis and papillary-like
thyroid carcinoma in heterozygous mice (Di Cristofano
et al. 1998). Superficially, one may imagine that these
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Figure 2 Protein domains of PTEN. The N-terminal phospha-
tase domain (amino acids 1–185) is shown with the catalytic core. The
missense mutations which have been crucial for the elucidation of the
cellular role of PTEN are highlighted in orange. Mutations at C124
render a lipid- and protein-phosphatase–inactive protein, whereas mu-
tations at G129 result in a lipid-phosphatase–inactive yet protein-
phosphatase–active PTEN. The C-terminal domain (amino acids
186–403) contains the lipid-binding C2 domain (amino acids 186–
351); PEST domains (amino acids 350–375 and 379–396), which reg-
ulate protein stability; and the PDZ domain, which is important in
protein-protein interactions. The CK2 phosphorylation sites (S380,
T382, and T383), which are important for stability, are indicated by
the blue asterisks (*).
are features found in human CS; however, they are not
(e.g., papillary thyroid carcinoma is rarely observed in
PTEN-mutation–positive CS or BRRS). In their mouse
model, Suzuki et al. (1998) found defects in the gener-
ation of mesodermal lineages, as well as hamartomatous
colonic polyps, which are not particularly reminiscent
of the human counterparts typical in CS or BRRS. They
also observed thymic lymphomas, which are not com-
ponents of either CS or BRRS. Interestingly, with long
follow-up, these mice developed breast cancer and en-
dometrial cancers, both of which are components of CS
(Stambolic et al. 2000). With follow-up, pheochromo-
cytomas also developed, although, to date, these neu-
roendocrine tumors have never been observed in CS or
BRRS. Finally, Podsypanina et al. (1999) observed fol-
licular and papillary thyroid tumors and atypical hy-
perplasia of the endometrium, features that, again, are
reminiscent of CS/BRRS but are not similar when ex-
amined in histologic detail. The type of mutation or
differences in the genetic background of the mice may
contribute to the differences observed in each model.
The lack of significant similarity to CS and BRRS raises
questions to the usefulness of these models in terms of
representing the clinical conditions. Nonetheless, these
models should prove useful, particularly when crossbred
with other knockout mice and/or for fundamental bio-
chemical studies, in elucidating information about the
pathways with which PTEN interacts in situ.
PTEN Structure: Does It Explain Phenotype?
Clinical and genetic analyses have revealed that PTEN
mutations result in an ever-widening spectrum of phe-
notypic features. Does the structure of PTEN yield clues
to explain this? Analysis of the crystal structure of PTEN
has identified two major domains (fig. 2).
The C-Terminal Domain
The C-terminal domain, in which 43% of PTEN
mutations occur, is composed of antiparallel b-sheets
that are linked together by short a-helices (Lee et al.
1999). This domain contains many important subdo-
mains that are common to other signal-transducingmol-
ecules. First, PTEN contains a C2 domain, which is as-
sociated with phospholipid-binding regions (Lee et al.
1999). C2 domains have been identified in many pro-
teins involved in signal transduction and membrane lo-
calization (Rizo and Sudhof 1998). Indeed, the C2 do-
main in PTEN has been shown to have affinity for
phospholipid membranes in vitro (Rizo and Sufhof
1998). Many germline PTEN mutations lie within the
C2 domain, suggesting its functional significance (figs.
1 and 2 and table 1). However, germline mutations
within the C2 domain have been found for the entire
spectrum of PHTS phenotypes (figs. 1 and 2), without
an obvious functional genotype-phenotype correlation.
Another feature of the C terminus is a PDZ-binding
motif, which interacts strongly with the phosphatase do-
main (described below; fig. 2) by both hydrogen bonding
and hydrophobic interactions (Lee et al. 1999). In ad-
dition, PDZ domains are significant regions for protein-
protein interactions (Fanning and Anderson 1999; Kay
et al. 2000), which play a vital role in cellular signal
transduction. Removal of the PDZ domain reduces the
ability of PTEN to inhibit one of its substrates, AKT
(Wu X. et al. 2000), suggesting that PTEN interactions
may be important in regulating PTEN activity. The C-
terminal tail also contains PEST sequences, which are
critical for PTEN stability (Georgescu et al. 1999). PEST
sequences target proteins for short intracellular half-lives
and protein degradation. Paradoxically, deletion of these
regions leads to decreased protein expression versus the
expected increase (Georgescu et al. 1999). Nonetheless,
these studies point out that the PEST regions are nec-
essary for PTEN stability.
The C-terminal tail also contains several phosphory-
lation sites located in the last 50 amino acids. Although
this region or “tail” of PTEN is unnecessary for phos-
phatase activity and cell-growth suppression (Vazquez
et al. 2000), it is critical for protein stability. Protein
stability is dependent on the phosphorylation of S380,
T382, and T383. Mutations of these sites reduced both
the protein half-life and the PTEN levels (Vazquez et al.
2000). Torres and Pulido (2001) demonstrated that
CK2, the protein kinase, phosphorylates PTEN in vivo
on serine residues 370, 380, and 385 and on threonine
residue 383. Furthermore, phosphorylation-defective
mutants have decreased protein stability and provided
evidence that dephosphorylated PTEN is degraded by
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proteasome-mediated mechanisms (Torres and Pulido
2001). Together, these data suggest that protein phos-
phorylation plays an important role in the regulation of
PTEN by influencing protein levels. PTEN phosphory-
lation has also been shown to cause a conformational
change that masks the PDZ domain, reducing PTEN’s
ability to bind to PDZ-domain–containing proteins
(Vazquez et al. 2000).
It is interesting to note that, to date, no germline or
somatic mutations have been detected specifically in the
PDZ, PEST, or phosphorylation sites, although there are
many mutations, both germline and somatic, that would
truncate the protein before these features. There are two
obvious explanations for these observations. This may
suggest that the presence of dominant negative muta-
tions within each of these domains may be embryonic
lethal while haploinsufficiency is viable, although it re-
sults in the PHTS phenotypes. It is difficult to imagine
that the alternate hypothesis—that is, that they are not
germane to carcinogenesis—could be true.
The N-Terminal Domain
The N-terminal domain contains the enzymatic side
of PTEN (i.e., its phosphatase domain), which is com-
posed of b-sheets surrounded by a-helices (Lee et al.
1999). The majority of PTEN mutations occur within
this domain. Analysis of the crystal structure revealed
that the PTEN phosphatase domain, although similar to
those of other protein phosphatases, has a slightly larger
active site. This enlarged active site allows for the ac-
cessibility of phospholipid substrates (Lee et al. 1999),
thereby making PTEN a unique phosphatase. The active
site is also a mutational hotspot, with ∼31% of germline
and somatic mutations occurring in exon 5, which en-
codes the catalytic core. That 40% of germline muta-
tions in CS lie in exon 5, which represents 20% of the
coding sequence, undoubtedly reflects the biology of the
resulting protein.
PTEN, a Dual-Specificity Phosphatase
Since the discovery of PTEN in 1997, abundant data have
been presented that show that PTEN is a tumor sup-
pressor in vitro and in vivo. PTEN can be regarded as a
dual-specificity phosphatase on several levels. In partic-
ular, recombinant PTEN has been shown to dephos-
phorylate protein substrates in vitro on serine, threonine,
and tyrosine residues (Myers et al. 1997). In this manner,
PTEN is a dual-specificity protein phosphatase. One pro-
posed PTEN substrate is focal adhesion kinase (FAK);
PTEN interacts with FAK and decreases its tyrosine phos-
phorylation levels (Gu et al. 1998; Tamura et al. 1998).
Dephosphorylation of FAK inhibits cell spreading, sug-
gesting that the protein-phosphatase activity of PTEN
may be important in the regulation of cellular interactions.
This, however, may be cell line–specific, since others have
been unable to reproduce this work.
In 1998, Maehama and Dixon reported another
PTEN substrate. Previous work had shown that the
PTEN mutant G129E, a mutation found in at least two
families with CS, still had the ability to dephosphorylate
peptide substrates in vitro (Maehama and Dixon 1998).
This suggested that PTEN may also have a nonprotein-
aceous target in vivo. Maehama and Dixon observed
that the overexpression of PTEN reduced the cellular
levels of phosphoinositol 3,4,5-triphosphate (PIP3) in
response to insulin. This occurred without a change in
the activity of PI3K, the kinase that phosphorylates
phosphoinositol-diphosphate. When the G129Emutant
was expressed in cell lines, PIP3 levels increased. To-
gether, these data suggested that PTEN was capable of
dephosphorylating cellular phospholipids. Meahama
and Dixon expanded their observations by showing that
PTEN catalyzes, in vivo and in vitro, the removal of
phosphate from the D3 position of the inositol ring.
Therefore, PTEN is also a dual-specificity phosphatase
in the sense that it dephosphorylates protein substrates
in addition to lipid substrates.
PTEN Regulation of the PI3K Pathway
Phosphoinositide second messengers play an important
role in signal transduction pathways that regulate cell
growth, differentiation, apoptosis, metabolism, actin re-
arrangements, and membrane trafficking. They do this
by directly activating enzymes or by directing proteins
to various subcellular locations via lipid binding. Abun-
dant data have shown that PIP3 is required for the ac-
tivation of AKT/PKB, a serine/threonine protein kinase
that plays a role in cell survival (Vazquez et al. 2000).
PI3K activation, mainly by growth factors, results in the
accumulation of PIP3 in cellular membranes (Kapeller
and Cantley 1994) resulting in the translocation of AKT
from cytoplasmic stores to cellular membranes. On
membrane docking, AKT undergoes a conformational
change and is phosphorylated by PDK1, thereby stim-
ulating AKT and subsequent signaling via its down-
stream effectors (fig. 3). This stimulates pathways re-
quired for cell survival and proliferation (Downward
1998).
PTEN antagonizes the PI3K/AKT pathway by de-
phosphorylating PIP3, resulting in a decreased trans-
location of AKT to cellular membranes and subsequent
down-regulation of AKT activation. Indeed, it has been
shown that expression of PTEN in cells leads to de-
creased levels of phospho-AKT, and, therefore, to in-
creased apoptosis (Davies et al. 1998; Myers et al.
1998). In addition, constitutively active, but not wild-
type, AKT, can rescue cells from PTEN-mediated G1
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Figure 3 PTEN as a regulator of the PI3K pathway. Ligand
binding to membrane receptors results in the activation of PI3K and
the subsequent increase in PIP3, which recruits PDK1 to the cellular
membrane. PDK1 phosphorylates and activates AKT, which in turn
regulates a variety of cellular processes. PTEN dephosphorylates PI3P,
lowering its cellular levels and resulting in the down-regulationofAKT.
arrest and apoptosis. Furthermore, PI3K inhibition by
LY294002 could mimic the effects of PTEN (Li and Sun
1998). Together, these data demonstrate that PTEN ex-
erts its effect upstream from PI3K.
The effect that PTEN has on the PI3K pathway is
phosphatase dependent. C124 is the active-site cysteine
of PTEN and has been found to be mutated in at least
three probands with CS (Marsh et al. 1998b; Bonneau
and Longy 2000). The C124S mutation abolishes both
the protein and lipid-phosphatase activities of PTEN
(Myers et al. 1998). When the PTEN C124S mutant was
introduced into cells, phospho-AKT levels remained con-
stant, and cells did not undergo G1 arrest or apoptosis
(Myers et al. 1998; Weng et al. 1999, 2001b).
Several groups have shown that PTEN coordinates
G1 arrest through up-regulation of p27 and concomi-
tant down-regulation of cyclin D1 (Cheney et al. 1999;
Bruni et al. 2000; Medema et al. 2000; Persad et al.
2001; Weng et al. 2001a). The D cyclins are key reg-
ulators of progression through G1 of the cell cycle,
whereas p27 is an inhibitor of cyclin-dependent kinases
and acts as a negative regulator of the cell cycle. Another
factor that influences G1 arrest may be the inhibition
of retinoblastoma protein phosphorylation via the ef-
fects that PTEN has on the PI3K pathway (Paramio et
al. 1999). Use of a G129E mutant has shed light on the
mechanisms by which PTEN exerts some of these ef-
fects. Similar to C124, G129 is also one of the key
residues in the active site of PTEN and has been found
to be mutated in at least three probands with CS. In-
terestingly, this mutation renders the PTEN molecule
lipid-phosphatase inactive but protein-phosphatase ac-
tive. Weng et al. (2001a) used both the G129E and
C124S mutants to determine that PTENdown-regulates
cyclin D1 expression by its protein-phosphatase activity.
In contrast, p27 levels are up-regulated downstream
from the lipid-phosphatase activity (Weng et al. 2001a).
In contrast, p27 levels, as well as p21 and p57 levels,
are up-regulated downstream from the lipid-phospha-
tase activity. Increased transcription of these cyclin-de-
pendent kinase inhibitors occurs in response to PTEN-
mediated down-regulation of AKT. This is believed to
be mediated by the Forkhead family of transcription
factors, and it also contributes to G1 arrest. Together,
these data indicate that PTEN’s lipid-phosphatase ac-
tivity is critical to cell function. In light of this, it is
interesting to note that 90% of PTEN missense muta-
tions eliminate or reduce lipid-phosphatase activity (ta-
ble 1), without affecting the ability of the protein to
bind to the cellular membrane (Han et al. 2000). Since
the PI3K pathway is involved in a variety of pathways,
including those for hypoxia-induced protein regulation
and obesity (reviewed in Katso et al. 2001; Minet et al.
2001), the phenotypic result of PTEN mutation could
be compounded by the as-yet-unknown effects of mul-
tiple downstream and feedback pathways.
Most naturally occurringmutations are both lipid- and
protein-phosphatase inactive (e.g., C124S; see table 1),
although a minority are lipid-phosphatase inactive but
protein-phosphatase active (e.g., G129E). It is interest-
ing that no naturally occurring mutation that results in
lipid-phosphatase–active but protein-phosphatase–in-
active PTEN has been identified. This is most likely
because a change in the active site that renders PTEN
protein-phosphatase inactive would automatically ren-
der the protein lipid-phosphatase inactive. However,
this does not necessarily mean that PTEN has no other
function than to regulate the PI3K pathway, as has been
suggested by emerging data (see next section).
Other Roles of PTEN
Although abundant data show that PTEN is a negative
regulator of the PI3K/AKT pathway, it is also becoming
clear that PTEN may be involved in other cellular func-
tions. For example, FAK has been proposed as a protein
substrate of PTEN (Tamura et al. 1998, 1999).
As is the PI3K pathway, the mitogen-activated kinase
(MAPK) pathway is another critical pathway for pro-
liferation and differentiation. PTEN also regulates this
pathway. PTEN can dephosphorylate Shc, resulting in
the inhibition of Grb2 and, ultimately, the down-reg-
ulation of MAPK. However, it has also been demon-
strated that PTEN can inhibit the MAPK pathway in a
Shc-independent manner (fig. 4). First, PTEN may reg-
ulate the MAPK pathway by modulating the movement
of Gab1 to the plasma membrane. Gab1 contains a
pleckstin-homology domain that interacts with PIP3-
rich membranes (Ong et al. 2001). By dephosphorylat-
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Figure 4 PTEN as a modulator of the MAPK pathway. PTEN
can inhibit the activation of MAPK by several mechanisms. By de-
phosphorylating Shc and/or IRS-1, PTEN prevents the association of
these proteins to the Sos:Grb complex, which is required for MAPK
activation. Gab interacts with the membrane by binding to PI3P
regions via the pleckstrin-homology domain. By decreasing the PI3P
levels in the membrane, PTEN inhibits the translocation of Gab to the
membrane and its subsequent activation of the MAPK pathways. The
entire pathway for MAPK activation and protein-protein interactions
has been omitted for clarity.
ing PIP3, PTEN would effectively prevent Gab1 from
translocating to the membrane, thus decreasing the ac-
tivation of MAPK (fig. 4) (Takahashi-Tezuka et al.
1998; Yart et al. 2001). Second, PTEN has been shown
to inhibit insulin stimulation of the MAPK pathway.
This inhibition results from the dephosphorylation of
the insulin-receptor substrate–1 (IRS-1), which inhibits
the formation of the IRS-1/Grb2/Sos complex, a com-
plex that is required for MAPK activation. This indi-
cates that PTEN can play a role in insulin signaling
(Weng et al. 2001c).
That PTEN has a central role in insulin signaling is
supported by further evidence: (1) PTEN expression in
adipocytes inhibits insulin-stimulated production of 2-
deoxyglucose (Nakashima et al. 2000). (2) PTEN ex-
pression inhibits Glut4 translocation, which is a key
event in insulin signaling (Nakashima et al. 2000); how-
ever, this line of evidence may be controversial, since
PTEN does not have such an effect in adipose cells
(Moser et al. 2001). (3) Insulin-receptor substrate–2
(IRS-2) has recently been shown to increase in the pres-
ence of PTEN (Simpson et al., in press). Together, this
evidence suggests other roles for PTEN besides the reg-
ulation of the PI3K pathway.
An interesting observation—with regard to alter-
native roles for PTEN besides the regulation of PI3K
or MAPK pathway—is that PTEN can be found in
the nuclear compartment (Tamura et al. 1998; Gimm
et al. 2000b; Lachyankar et al. 2000; Perren et al.
2000; Whiteman et al., in press). PTEN lacks a clear
nuclear-localization sequence, and the mechanism of
its transport into the nuclear compartment is still be-
ing elucidated. Immunohistochemistry analysis dem-
onstrated that PTEN expression in the nuclear com-
partment is higher in normal tissue than in
counterpart neoplastic tissue found in the thyroid,
endocrine pancreas, and primary cutaneous mela-
nomas (Gimm et al. 2000b; Perren et al. 2000; White-
man et al., in press). The significance of this obser-
vation is still under investigation. Because PTEN can
regulate transcription via the PI3K pathway, which
is found predominantly at the plasma membrane
(Datta et al. 1999; Dong et al. 1999), does the lo-
calization of PTEN to the nuclear compartment se-
quester PTEN and reduce PI3K-dependent transcrip-
tion of pro-proliferative factors? Alternatively,
nuclear PTEN could act on lipids in the nuclear
membrane. Although the level of phosphoinositol in
the nuclear membrane is low, it is present, along with
PI3K (D’Santos et al. 1998; Marchisio et al. 1998;
Martelli et al. 1999; Metjian et al. 1999). Thus, the
trafficking of PTEN to the nuclear compartment may
activate transcription of pro-apoptotic pathways, as
it does at the plasma membrane. Many transcription
factors are regulated by their phosphorylation, and
a promising alternative hypothesis is that PTEN may
regulate the activity of various transcription factors
via direct dephosphorylation in the nucleus. Future
investigations into the function of nuclear PTEN
should prove to be enlightening.
The Present and the Future
What does the future hold for PTEN research? Un-
doubtedly, we will learn more about the mechanisms by
which PTEN regulates the PI3K, MAPK, and insulin-
signaling pathways, but it is naive to think that these
are the only pathways that PTEN influences. Enough
evidence is currently present to surmise that PTEN may
play a role in the regulation of a variety of disease states
and metabolic processes. In this era of genomics/pro-
teomics, array analysis will certainly yield more clues to,
as well as more puzzles about, the roles that PTEN plays.
Indeed, the up-regulation of IRS-2 by PTEN was dem-
onstrated by microarray expression analysis (Simpson et
al., in press). Unoki and Nakamura have used global
expression analysis to demonstrate that EGR2 and
BPOZ are involved in PTEN signaling (Unoki and Nak-
amura 2001). EGR2 is part of a multigene family that
contains C2H2-type zinc-finger proteins (Joseph et al.
1998), and germline mutations in this transcription fac-
tor gene have been implicated in Charcot-Marie-Tooth
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syndrome (MIM 118200) and congenital hypomyeli-
nating neuropathy (MIM 605253) (Warner et al. 1998).
The association between PTEN and EGR2 is interesting,
because prominent PTEN expression has been demon-
strated in the CNS and neural crest throughout human
development (Gimm et al. 2000a) and because a subset
of patients with CS have signs of neuropathy (C. Eng,
unpublished data). Other expression-array studies have
implicated PTEN in the regulation of members of the
tumor necrosis factor (TNF)–receptor family, TNF-as-
sociated genes, and members of both theMad andNotch
signaling families (Hong et al. 2000;Matsushima-Nishiu
et al. 2001). Additional array studies will undoubtedly
discover more protean pathways, as well as “red her-
rings,” downstream from PTEN.
PTEN appears to be constitutively active. Thus, the
regulation of PTEN levels via transcription, translation,
and posttranslational means remains to be investigated
in depth. We now know that phosphorylation of the C-
terminal tail of PTEN by CK2 can negatively regulate
the stability of PTEN (discussed in the “C-Terminal Do-
main” subsection of “PTEN Structure,” above). What
we do not know is the identity of the phosphatase that
dephosphorylates PTEN. Phosphorylation and dephos-
phorylation are the yin and yang of signal transduction;
thus, the phosphatase must be there, yet it remains un-
identified. Preliminary data have recently been pub-
lished on the regulation of PTEN transcription. Acti-
vated PPARg, p53, and EGR1 have been shown to
up-regulate PTEN transcription (Patel et al. 2001; Stam-
bolic et al. 2001; Virolle et al. 2001). Factors that may
down-regulate transcription have yet to be identified.
Copious amounts of data have demonstrated that
PTEN can influence signal transduction via its phos-
phatase activity. What remains to be determined is if
PTEN can influence pathways by other mechanisms. As
described above, PTEN contains many signaling do-
mains (e.g., PEST and PDZ). It is interesting to postulate
that these domains may also play a role in signal trans-
duction. PTEN has been shown, via yeast two-hybrid
studies, to associate with membrane-associated guan-
ylate-kinase inverted (MAGI) proteins, which contain
PDZ domains and are localized to tight junctions (Wu
X. et al. 2000; Wu Y. et al. 2000). Additional studies
suggest that the interaction between PTEN and MAGI
may enhance the stability of PTEN (Wu X. et al. 2000).
Although this interaction seems to regulate PTEN ac-
tivity, an appealing proposal is that PTEN may interact
with other signaling molecules to modulate specific
pathways in a phosphatase-independent manner; how-
ever, this needs to be proved.
In this era of genetics, data generated in the lab-
oratory should be translated to the practice of ge-
nomic medicine. Already, we are able to use PTEN-
mutation analysis for predictive testing within
PTEN-mutation–positive families, and we can use
PTEN testing as a molecular-diagnostic tool to sort
out a group of difficult-to-diagnose inherited hamar-
toma-tumor syndromes. Classification of these pro-
tean clinical syndromes by molecular identity is be-
l i eved to be use fu l in the pred ic t ion of the
development of neoplasias and the recommendation
of surveillance. However, the mechanisms by which
identical mutations result in phenotypes as diverse as
CS, BRRS, and PS is, as yet, unknown. The challenge
for the next decade is to determine the gene-gene in-
teractions and gene-environment interactions that
arise in different tissue-specific contexts to result in
a specific phenotype.
The brave new world would be incomplete without
an attempt to utilize molecular-based knowledge to
create a novel treatment. Since overwhelming data
demonstrate that the PI3K/AKT pathway lies down-
stream from PTEN and that mTOR (i.e., mammalian
target of rapamycin) is downstream from—or, at
least, acts in concert with—the PI3K/AKT pathway,
rapamycin and its analogs have been hailed as the
“magic bullet” that will cure all the ailments of a sick
PTEN (Mills et al. 2001; Neshat et al. 2001). How-
ever, the PI3K/AKT and mTOR pathways merely lie
downstream from PTEN’s lipid-phosphatase activity.
Virtually all enzymatic activity–abrogating mutations
affect the lipid- and protein-phosphatase activity.
Thus, it would be predicted that drugs that target
only downstream from the lipid-phosphatase activity
would not be completely effective and might, in fact,
cause harm. Nevertheless, this is an auspicious start.
The challenge for the future is to have “designer
drugs” that target in a manner that takes into account
the genomic, epigenomic, and proteomic milieu. To
achieve this, not only should efforts be made in ge-
nomic, epigenomic, and proteomic research, which is
already happening, but these data must also be linked
with comprehensive and meticulous clinical and cel-
lular phenotypic data, which we call “phenomics.”
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Appendix A
Common Manifestations of CS
Mucocutaneous lesions (90%–100%):
Trichilemmomas
Acral keratoses
Verucoid or papillomatous papules
Thyroid abnormalities (50%–67%):
Goiter
Adenoma
Cancer (3%–10%)
Breast lesions:
Fibroadenomas/fibrocystic disease (76% of affected females)
Adenocarcinoma (25%–50% of affected females)
Gastrointestinal lesions (40%): hamartomatous polyps
Macrocephaly (38%)
Genito-urinary abnormalities (44% of females): uterine leiomyoma (multiple, early onset)
Appendix B
International Cowden Consortium Operational Diagnostic Criteria: 2000 Version
Operational diagnostic criteria are reviewed and revised on a continuous basis, as new clinical and genetic
information becomes available. The 1995 and 2000 versions have been accepted by the U.S.-based NCCN High
Risk/Genetics Panel.
Pathognomonic criteria (mucocutaneous lesions):
Facial trichilemmomas
Acral keratoses
Papillomatous papules
Mucosal lesions
Major criteria:
Breast carcinoma
Thyroid carcinoma (nonmedullary), especially follicular thyroid carcinoma
Macrocephaly (megalencephaly; e.g., 97th percentile)
Lhermitte-Duclos disease (LDD)
Endometrial carcinoma
Minor criteria:
Other thyroid lesions (e.g., adenoma or multinodular goiter)
Mental retardation (e.g., intelligence quotient 75)
Gastrointestinal hamartomas
Fibrocystic disease of the breast
Lipomas
Fibromas
Genito-urinary tumors (e.g., renal cell carcinoma or uterine fibroids) or malformation
Operational diagnosis in an individual:
1. Mucocutaneous lesions alone if there are (a) six or more facial papules, of which three or more must be
trichilemmoma; (b) cutaneous facial papules and oral mucosal papillomatosis; (c) oral mucosal papillom-
atosis and acral keratoses; or (d) six or more palmar or plantar keratoses
2. Two major criteria, of which one must be macrocephaly or LDD
3. One major and three minor criteria
4. Four minor criteria
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Operational diagnosis in a family in which one individual has had a diagnosis of CS:
1. One or more of pathognomonic criteria
2. Any one major criterion with or without minor criteria
3. Two minor criteria
Electronic-Database Information
Accession numbers and the URL for data in this article are
as follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for Charcot-Marie-Tooth syn-
drome [MIM 118200], BRRS [MIM 153480], CS [MIM
158350], JPS [MIM 174900], PJS [MIM 175200], PS
[MIM 176920], congenital hypomyelinating neuropathy
[MIM 605253], and PTEN/MMAC1/TEP1 [MIM601728])
References
Ahmed SF, Marsh DJ, Weremowicz S, Morton CC, Williams
DM, Eng C (1999) Balanced translocation of 10q and 13q,
including the PTEN gene, in a boy with an HCG-secreting
tumor and the Bannayan-Riley-Ruvalcaba syndrome. J Clin
Endocrinol Metab 84:4665–4670
Arch EM, Goodman BK, van Wesep RA, Liaw D, Clarke K,
Parsons R, McKusick VA, Geraghty MT (1997) Deletion of
PTEN in a patient with Bannayan-Riley-Ruvalcaba syn-
drome suggests allelism with Cowden disease. Am J Med
Genet 71:489–493
Barker E, Martinez A, Wang R, Bevan S, Murday V, Shipley
J, Houlston R, Harper J (2001) PTEN mutations are un-
common in Proteus syndrome. J Med Genet 38:480–481
Biesecker LG, Happle R, Mulliken JB, Weksberg R, Graham
JM, Viljoen DL, Cohen MM (1999) Proteus syndrome: di-
agnostic criteria, differential diagnosis and patient evalua-
tion. Am J Med Genet 84:389–395
Bonneau D, Longy M (2000) Mutations of the human PTEN
gene. Hum Mutat 16:109–122
Bruni P, Boccia A, Baldasarre G, Trapasso F, Santoro M,
Chiappetta G, Fusco A, Viglietto G (2000) PTEN expression
is reduced in a subset of sporadic thyroid carcinomas: evi-
dence that PTEN-growth suppressing activity in thyroid can-
cer cells is mediated by p27kip1. Oncogene 19:3146–3155
Carethers JM, Furnari FB, Zigman AF, Lavine JE, Jones MC,
Graham GE, Teebi AS, SuHuang HJ, Ha HT, Chauhan DP,
Chang CL, Cavanee WK, Boland CR (1998) Absence of
PTEN/MMAC1 germline mutations in sporadic Bannayan-
Riley-Ruvalcaba syndrome. Cancer Res 58:2724–2726
Celebi JT, Tsou HC, Chen FF, Zhang H, Ping XL, Lebwohl
MG, Kezis J, Peacocke M (1999) Phenotypic findings of
Cowden syndrome and Bannayan-Riley-Ruvalcaba syn-
drome in a family associated with a single germlinemutation
in PTEN. J Med Genet 36:360–364
Cheney IW, Neuteboom STC, VaillancourtM-T, Ramachandra
M, Bookstein R (1999) Adenovirus-mediated gene entry of
MMAC1/PTEN to glioblastoma inhibits S phase entry by
the recruitment of p27Kip1 and cyclin E/CDK2 complexes.
Cancer Res 59:2318–2323
Dahia PLM, Gimm P, Chi H, Marsh DJ, Reynolds PR, Eng
C (2000) Absence of germline mutations in MINPP1, a
phosphatase-encoding gene centromeric of PTEN, in pa-
tients with Cowden and Bannayan-Riley-Ruvalcaba syn-
drome without germline PTEN mutations. J Med Genet
37:715–717
Dasouki MJ, Ishmael H, Eng C (2001) Macrocephaly, macro-
somia and autistic behavior due to a de novo PTEN germline
mutation. Am J Hum Genet Suppl 69:S280
Datta SR, Brunet A, Greenberg ME (1999) Cellular survival:
a play in three Akts. Genes Dev 13:2905–2927
Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPuschin R, Koul
D, Bookstein R, Stokoe D, Yung WKA, Mills GB, Steck PA
(1998) Adenoviral transgene expression of MMAC/PTEN
in human glioma cells inhibits Akt activation and induces
anoikis. Cancer Res 58:5285–5290
De Vivo I, Gertig D, Nagase S, Hankinson SE, O’Brien R,
Speizer FE, Parsons R, Hunter DJ (2000) Novel germline
mutations in the PTEN tumour suppressor gene found in
women with multiple cancers. J Med Genet 37:336–341
Devriendt K, DeCock P, Fryns JP (1995) Hydrocephalus with
features of VATER. J Genet Couns 6:69
Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998)
Pten is essential for embryonic development and tumour
suppression. Nat Genet 19:348–355
Dong Z, Huang C, Ma WY (1999) PI-3 kinase in signal trans-
duction, cell transformation, and as a target for chemo-
prevention of cancer. Anticancer Res 19:3743–3747
Downward J (1998) Mechanisms and consequences of activa-
tion of protein kinase B/Akt. Curr Opin Genet Dev 8:49–54
D’Santos CS, Clarke JH, Divecha N (1998) Phospholipid sig-
nalling in the nucleus. Biochim Biophys Acta 1436:201–232
Eng C (1997) Cowden syndrome. J Genet Couns 6:181–191
——— (1998) Genetics of Cowden syndrome: through the
looking glass of oncology. Int J Oncol 12:701–710
——— (2000) Will the real Cowden syndrome please stand
up: revised diagnostic criteria. J Med Genet 37:828–830
——— (2001) To be or not to BMP. Nat Genet 28:105–107
Eng C, Brody LC, Wagner TMU, Devilee P, Vijg J, Szabo C,
Tavtigian S, Nathanson KL, Ostrander E, Frank TS, Breast
Cancer Information Core Consortium (2001) Interpretation
of molecular epidemiologic research: blinded comparison of
methods for detecting germline BRCA1 mutations. J Med
Genet 38:824–833
Eng C, Ji H (1998) Molecular classification of the inherited
hamartoma polyposis syndromes: clearing the muddied wa-
ters. Am J Hum Genet 62:1020–1022
Fackenthal J, Marsh DJ, Richardson AL, Cummings SC, Eng
C, Robinson BG, Olopade OI (2001) Male breast cancer in
Waite and Eng: Features of PTEN 841
Cowden syndrome patients with germline PTENmutations.
J Med Genet 38:159–164
Fanning AS, Anderson JM (1999) Protein modules as organizers
of membrane structure. Curr Opin Cell Biol 11:432–439
Georgescu M-M, Kirsch KH, Akagi T, Shishido T, Hanafusa
H (1999) The tumor-suppressor activity of PTEN is regu-
lated by its carboxy-terminal region. ProcNatl Acad Sci USA
96:10182–10187
GimmO, Attie´-Bitach T, Lees JA, VekemensM, Eng C (2000a)
Expression of PTEN protein in human embryonic devel-
opment. Hum Mol Genet 9:1633–1639
Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U,
Gil E, Hinze R, Delbridge L, Lees JA, Robinson BG, Kom-
minoth P, Dralle H, Eng C (2000b) Differential nuclear and
cytoplasmic expression of PTEN in normal thyroid tissue,
and benign and malignant epithelial thyroid tumors. Am J
Pathol 156:1693–1700
Gorlin RJ, Cohen MM, Condon LM, Burke BA (1992) Ban-
nayan-Riley-Ruvalcaba syndrome. Am J Med Genet 44:
307–314
Gu J, Tamura M, Yamada KM (1998) Tumor suppressor
PTEN inhibits integrin- and growth factor-mediated mito-
gen-activated protein (MAP) kinase signaling pathway. J
Cell Biol 143:1375–1383
Han S-Y, Kato H, Suzuki T, Shibata H, Ishii S, Shiba K, Mat-
suno S, Kanamaru R, Ishioka C (2000) Functional evalua-
tion of PTEN missense mutations using in vitro phospho-
inositide phosphatase assay. Cancer Res 60:3147–3151
Hanssen AMN, Fryns JP (1995) Cowden syndrome. J Med
Genet 32:117–119
Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S,
Loukola A, Bignell G, Aminoff WM, Ho¨gland P, Ja¨rvinen
H, Kristo P, Pelin K, Ridanpa¨a¨ M, Salovaara R, Toro T,
Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la
Chapelle A, Aaltonen LA (1998) A serine/threonine kinase
gene defective in Peutz-Jeghers syndrome. Nature 391:
184–187
Hemminki A, Tomlinson I, Markie D, Ja¨rvinen H, Sistonen P,
Bjo¨rkqvist A-M, Knuutila S, Salovaara R, Bodmer W, Shi-
bata D, de la Chapelle A, Aaltonen LA (1997) Localisation
of a susceptibility locus for Peutz-Jeghers syndrome to 19p
using comparative genomic hybridization and targeted link-
age analysis. Nat Genet 15:87–90
Hong TM, Yang PC, Peck K, Chen JJ, Yang YC, Chen YC,
Wu CW (2000) Profiling the downstream genes of tumor
suppressor PTEN in lung cancer cells by complementary
DNA microarray. Am J Respir Cell Mol Biol 23:355–363
Howe JR, Blair JA, Sayed MG, Anderson ME, Mitros FA,
Petersen GM, Velculescu VE, Traverso G, Vogelstein B
(2001) Germline mutations of BMPR1A in juvenile poly-
posis. Nat Genet 28:184–187
Howe JR, Ringold JC, Summers RW, Mitros FA, Nishimura
DY, Stone EM (1998a) A gene for familial juvenile poly-
posis maps to chromosome 18q21.1. Am J Hum Genet 62:
1129–1136
Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sis-
tonen P, Tomlinson IPM, Houlston RS, Bevan S, Mitros FA,
Stone EM, Aaltonen LA (1998b) Mutations in the SMAD4/
DPC4 gene in juvenile polyposis. Science 280:1086–1088
Huang SC, Chen CR, Lavine JE, Taylor SF, Newbury RO,
Pham TT, Ricciardiello L, Carethers JM (2000) Genetic
heterogeneity in familial juvenile polyposis. Cancer Res 60:
6882–6885
Iafolla AK, McConkie-Rosell A, Chen YT (1991) VATER
and hydrocephalus: distinct syndrome? Am J Med Genet
38:46–51
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R,
Mu¨ller O, Back W, Zimmer M (1998) Peutz-Jeghers syn-
drome is caused by mutations in a novel serine threonine
kinase. Nat Genet 18:38–44
Joseph JL, LeBeau MM, Jamieson GA, Acharya S, Shows TB,
Rowley JD, Sukhatme VP (1998) Molecular cloning, se-
quencing, and mapping of EGR2, a human early growth
response gene encoding a protein with “zinc-binding finger”
structure. Proc Natl Acad Sci USA 85:7164–7168
Kapeller R, Cantley LC (1994) Phosphoinositol 3-kinease.
Bioessays 16:565–576
Katso R, Okkenbaug K, Ahmadi K, White S, Timms J, Wa-
terfield MD (2001) Cellular function of phosphoinositide 3-
kinases: implications for development, homeostasis, and
cancer. Annu Rev Cell Dev Biol 17:615–675
Kay BK, Williamson MP, Sudol M (2000) The importance of
being proline: the interaction of proline-rich motifs in sig-
naling proteins with their cognate domains. FASEB J 14:
231–241
Kurose K, Araki T, Matsunaka T, Takada Y, Emi M (1999)
Variant manifestation of Cowden disease in Japan: hamar-
tomatous polyposis of the digestive tract with mutation of
the PTEN gene. Am J Hum Genet 64:308–310
Lachyankar MB, Sultana N, Schonhoff CM, Mitra P, Poluha
W, Lambert S, Quesenberry PJ, Litofsky NS, Recht LD,Nabi
R, Miller SJ, Ohta S, Neel BG, Ross AH (2000) A role for
nuclear PTEN in neuronal differentiation. J Neurosci 20:
1404–1413
Lee J, Yang H, Georgescu M-M, Di Cristafano A, Maehama
T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP (1999) Crystal
structure of the PTEN tumor suppressor: implications for
its phosphoinositide phosphatase activity and membrane as-
sociation. Cell 99:323–334
Li D-M, Sun H (1997) TEP1, encoded by a candidate tumor
suppressor locus, is a novel protein tyrosine phosphatase
regulated by transforming growth factor B. Cancer Res 57:
2124–2129
Li DM, Sun H (1998) PTEN/MMAC1/TEP1 suppresses the
tumorigenecity and induces G1 cell cycle arrest in human
glioblastoma cells. Proc Natl Acad Sci USA 95:15406–
15411
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Puc J,
Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giova-
nella BC, Ittman M, Tycko B, Hibshoosh H, Wigler MH,
Parsons R (1997) PTEN, a putative protein tyrosine phos-
phatase gene mutated in human brain, breast and prostate
cancer. Science 275:1943–1947
Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose
S, Call KM, Tsou HC, PeacockeM, Eng C, Parsons R (1997)
Germline mutations of the PTEN gene in Cowden disease,
an inherited breast and thyroid cancer syndrome. Nat Genet
16:64–67
Longy M, Coulon V, Duboue´ DA, Larre`gue M, Eng C, Amati
P, Kraimps J-L, Bottani A, Lacombe D, Bonneau D (1998)
842 Am. J. Hum. Genet. 70:829–844, 2002
Mutations of PTEN in patients with Bannayan-Riley-Ru-
valcaba phenotype. J Med Genet 35:886–889
Longy M, Lacombe D (1996) Cowden disease: report of a
family and review. Ann Genet 39:35–42
Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji H, Dann J,
Swisshelm K, Suchard D, MacLeod PM, Kvinnsland S,
Gjertsen BT, Heimdal K, Lubs H,Møller P, KingM-C (1997)
Inherited mutations in PTEN that are associated with breast
cancer, Cowden syndrome, and juvenile polyposis. Am J
Hum Genet 61:1254–1260
Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/
MMAC1, dephosphorylates the lipid secondmessenger phos-
phoinositol 3,4,5-triphosphate. J Biol Chem 273:13375–
13378
Mallory SB (1995) Cowden syndrome (multiple hamartoma
syndrome). Dermatol Clin 13:27–31
Marchisio M, Bertagnolo V, Colamussi ML, Capitani S, Neri
LM (1998) Phosphotidylinositol 3-kinase in HL-60 nuclei
is bound to the nuclear matrix and increases during gran-
ulocyte differentiation. Biochem Biophys Res Commun 253:
346–351
Marsh DJ, Caron S, Dahia PLM, Kum JB, Frayling IM, Tom-
linson IPM, Hughes KS, Hodgson SV,Murday VA,Houlston
R, Eng C (1998a) Germline PTEN mutations in Cowden
syndrome-like families. J Med Genet 35:881–885
Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PLM,
Zheng Z, Liaw D, et al (1998b) Mutation spectrum and
genotype-phenotype analyses in Cowden disease and Ban-
nayan-Zonana syndrome, two hamartoma syndromes with
germline PTEN mutation. Hum Mol Genet 7:507–515
Marsh DJ, Dahia PLM, Zheng Z, Liaw D, Parsons R, Gorlin
RJ, Eng C (1997a) Germline mutations in PTEN are present
in Bannayan-Zonana syndrome. Nat Genet 16:333–334
Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ah-
med SF, Bodurtha J, et al (1999) PTEN mutation spectrum
and genotype-phenotype correlations in Bannayan-Riley-
Ruvalcaba syndrome suggest a single entity with Cowden
syndrome. Hum Mol Genet 8:1461–1472
Marsh DJ, Roth S, Lunetta K, Hemminki A, Dahia PLM, Sis-
tonen P, Zheng Z, et al (1997b) Exclusion of PTEN and
10q22-24 as the susceptibility locus for juvenile polyposis
syndrome (JPS). Cancer Res 57:5017–5021
Martelli AM, Capitani S, Neri LM (1999) The generation of
lipid signaling molecules in the nucleus. Prog Lipid Res 38:
273–308
Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Mina-
gucki T, Kuramoto H, Nishida M, Satoh T, Tanaka T, Naka-
mura Y (2001) Growth and gene expression profile analyses
of endometrial cancer cells expressing exogenous PTEN.Can-
cer Res 61:3741–3749
Medema RH, Kops GJ, Bos JL, Burgering BM (2000) AFX-
like Forkhead transcription factors mediate cell-cycle reg-
ulation by Ras and PKB through p27kip1. Nature 404:
782–787
Metjian A, Roll RL,Ma AD, Abrams CS (1999) Agonists cause
nuclear translocation of phosphotidylinositol 3-kinase g: a
Gbg-dependent pathway that requires p110g amino ter-
minus. J Biol Chem 274:27943–27947
Mills GB, Lu Y, Kohn EC (2001) Linking molecular thera-
peutics to molecular diagnostics: inhibition of the FRAP/
RAFT/TOR component of the PI3K pathway preferentially
blocks PTEN mutant cells in vitro and in vivo. Proc Natl
Acad Sci USA 98:10031–10033
Minet E, Michel G, Mottet D, Raes M, Michiels C (2001)
Transduction pathways involved in hypoxia-inducible fac-
tor-1 phosphorylation and activation. Free Radic Biol Med
31:847–855
Mosser VA, Li Y, Quon MJ (2001) PTEN does not modulate
GLUT4 translocation in rat adipose cells under physiological
conditions. Biochem Biophys Res Commun 288:1011–1017
Myers MP, Pass I, Batty IH, van der Kaay J, Storalov JP, Hem-
mings BA, Wigler MH, Downes CP, Tonks NK (1998) The
lipid phosphatase activity of PTEN is critical for its tumor
suppressor function. Proc Natl Acad Sci USA 95:13513–
13518
Myers MP, Stolarov J, Eng C, Li J, Wang SI, Wigler MH,
Parsons R, Tonks NK (1997) PTEN, the tumor suppressor
from human chromosome 10q23, is a dual specificity phos-
phatase. Proc Natl Acad Sci USA 94:9052–9057
Nakashima N, Sharma PM, Imamura T, Bookstein R, Olefsky
JM (2000) The tumor suppressor PTEN negatively regulates
insulin signaling in 3T3-L1 adipocytes. J Biol Chem 275:
12889–12895
NCCN Genetics/High Risk Panel (1999) NCCN practice
guidelines: genetics/familial high risk cancer. Oncology 13:
161–186
Nelen MR, Kremer H, Konings IBM, Schoute F, van Essen AJ,
Koch R, Woods CG, Fryns J-P, Hamel B, Hoefsloot LH,
Peeters EAJ, Padberg GW (1999) Novel PTEN mutations
in patients with Cowden disease: absence of clear genotype-
phenotype correlations. Eur J Hum Genet 7:267–273
Nelen MR, Padberg GW, Peeters EAJ, Lin AY, van den Helm
B, Frants RR, Coulon V, Goldstein AM, van Reen MMM,
Easton DF, Eeles RA, Hodgson S, Mulvihill JJ, Murday VA,
Tucker MA, Mariman ECM, Starink TM, Ponder BAJ, Rop-
ers HH, Kremer H, Longy M, Eng C (1996) Localization
of the gene for Cowden disease to 10q22-23. Nat Genet 13:
114–116
Nelen MR, van Staveren CG, Peeters EAJ, Ben Hassel M,
Gorlin RJ, Hamm H, Lindboe CF, Fryns J-P, Sijmons RH,
Woods DG, Mariman ECM, Padberg GW, Kremer H (1997)
Germline mutations in the PTEN/MMAC1 gene in patients
with Cowden disease. Hum Mol Genet 6:1383–1387
Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Pe-
tersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001)
Enhanced sensitivity of PTEN-deficient tumors to inhibition
of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319
Olschwang S, Serova-Sinilnikova OM, Lenoir GM, Thomas
G (1998) PTEN germline mutations in juvenile polyposis
coli. Nat Genet 18:12–14
Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax
I (2001) Stimulation of phosphatidylinositol 3-kinase by fi-
broblast growth factor receptors is mediated by coordinated
recruitment of multiple docking proteins. Proc Natl Acad
Sci USA 22:6074–6079
Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jor-
cano JL (1999) PTEN tumour suppressor is linked to the
cell cycle control through the retinoblastoma protein. On-
cogene 18:7462–7468
Patel L, Pass I, Coxon P, Downes CP, Smith SA, MacPhee CH
Waite and Eng: Features of PTEN 843
(2001) Tumor suppressor and anti-inflammatory actions of
PPARg agonists are mediated via upregulation of PTEN.
Curr Biol 11:764–768
Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S,
Lees JA, Heitz PU, Eng C (2000) Mutation and expression
analyses reveal differential subcellular compartmentaliza-
tion of PTEN in endocrine pancreatic tumors compared to
normal islet cells. Am J Pathol 157:1097–1103
Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar
S (2001) Tumor suppressor PTEN inhibits nuclear accumu-
lation of b-catenin and T cell/lymphoid enhancer factor 1–
mediated transcriptional activation. J Cell Biol 153:1161–
1174
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M,
Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Par-
sons R (1999) Mutation of Pten/Mmac1 in mice causes neo-
plasia in multiple organ systems. Proc Natl Acad Sci USA
96:1563–1568
ReardonW, ZhouXP, Eng C (2001) A novel germlinemutation
of the PTEN gene in a patient with macrocephaly, ventric-
ular dilatation and features of VATER association. J Med
Genet 38:820–823
Rizo J, Sudhof TC (1998) C2 domains, structure and function
of a universal C2-binding domain. J Biol Chem 273:
15879–15882
Simpson L, Li J, Liaw D, Hennessey I, Oliner J, Christians F,
Parsons R. PTEN expression causes a feedback upregulation
of IRS-2 signaling. Mol Cell Biol (in press)
Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y,
Benchimol S, Mak TW (2001) Regulation of PTEN tran-
scription by p53. Mol Cell 8:317–325
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos
C, Sasaki T, Rulland J, Penninger JM, Siderovski DP, Mak
TW (1998) Negative regulation of PKB/Akt-dependent cell
survival by the tumor suppressor PTEN. Cell 95:1–20
Stambolic V, Tsao MS, MacPherson D, Suzuki A, Chapman
WB, Mak TW (2000) High incidence of breast and endo-
metrial neoplasia resembling human Cowden syndrome in
pten / mice. Cancer Res 60:3605–3611
Starink TM, van der Veen JPW, Arwert F, deWaal LP, de Lange
GG, Gille JJP, Eriksson AW (1986) The Cowden syndrome:
a clinical and genetic study in 21 patients. Clin Genet 29:
222–233
Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon
AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye
C, Hu R, Swedlund B, Teng DHF, Tavtigian SV (1997) Iden-
tification of a candidate tumour suppressor gene, MMAC1,
at chromosome 10q23.3 that is mutated in multiple ad-
vanced cancers. Nat Genet 15:356–362
Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del
Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W,
Fukumoto M, Mak TW (1998) High cancer susceptibility
and embryonic lethality associated with mutation of the
PTEN tumor suppressor gene in mice. Curr Biol 8:1169–
1178
Takahashi-Tezuka M, Yoshida Y, Fukada T, Ohtani T, Ya-
manaka Y, Nishida K, Nakajima K, Hibi M, Hirano T
(1998) Gab1 acts as an adapter molecule linking the cyto-
kine receptor gp130 to ERK mitogen-activated protein ki-
nase. Mol Cell Biol 18:4109–4117
Tamura M, Gu J, Danen EHJ, Takino T, Miyamoto S, Yamada
KM (1999) PTEN interactions with focal adhesion kinase
and suppression of the extracellular matrix-dependent phos-
photidyinositol 3-kinase/Akt cell survival pathway. J Biol
Chem 274:20693–20703
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada
KM (1998) Inhibition of cell migration, spreading and focal
adhesions by tumor suppressor PTEN. Science 280:1614–
1617
Torres J, Pulido R (2001) The tumor suppressor PTEN is
phosphorylated by the protein kinase CK2 at its C ter-
minus. Implications for PTEN stability to proteasome-
mediated degradation. J Biol Chem 276:993–998
Tsou HC, Teng D, Ping XL, Broncolini V, Davis T, Hu R, Xie
X-X, Gruener AC, Schrager CA, Christiano AM, Eng C,
Steck P, Ott J, Tavtigian SV, Peacocke M (1997) Role of
MMAC1 mutations in early onset breast cancer: causative
in association with Cowden’s syndrome and excluded in
BRCA1-negative cases. Am J Hum Genet 61:1036–1043
Unoki M, Nakamura Y (2001) Growth-suppressive effects of
BPOZ and EGR2, two genes involved in the PTEN signaling
pathway. Oncogene 20:4457–4465
Vazquez F, Ramaswamy D, Nakamura N, Sellers WR (2000)
Phosphorylation of the PTEN tail regulates protein stability
and function. Mol Cell Biol 20:5010–5018
Virolle T, Adamson ED, Baron V, Birle D,Mercola D,Mustelin
T, de Belle I (2001) The Egr-1 transcription factor directly
activates PTEN during irradiation-induced signalling. Nat
Cell Biol 3:1124–1128
Wanner M, Celebi JT, Peacocke M (2001) Identification of a
PTEN mutation in a family with Cowden syndrome and
Bannayan-Zonana syndrome. J Am Acad Dermatol 44:
183–187
Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L,
Koob KG, Lupski JR (1998) Mutations in the early growth
response 2 (EGR2) gene are associated with hereditary mye-
linopathies. Nat Genet 18:382–384
Weng LP, Brown JL, Eng C (2001a) PTEN coordinates G1
arrest by down regulating cyclin D1 via its protein phos-
phatase activity and up regulating p27 via its lipid phos-
phatase activity. Hum Mol Genet 10:599–604
——— (2001b) PTEN induces apoptosis and cell cycle arrest
through phosphoinositol-3-kinase/Akt-dependent and in-
dependent pathways. Hum Mol Genet 10:237–242
Weng LP, Smith WM, Brown JL, Eng C (2001c) PTEN inhibits
insulin-stimulated MEK/MAPK activation and cell growth
by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos
complex formation in a breast cancer model. Hum Mol Ge-
net 10:605–616
Weng L-P, Smith WM, Dahia PLM, Ziebold U, Gil E, Lees JA,
Eng C (1999) PTEN suppresses breast cancer cell growth
by phosphatase function-dependent G1 arrest followed by
apoptosis. Cancer Res 59:5808–5814
Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward
NK, Eng C. PTEN expression and clinico-pathologic fea-
tures in a population-based series of primary cutaneous mel-
anoma. Int J Cancer (in press)
Wu X, Hepner K, Castello-Prabhu S, Do D, Kaye MB, Yuan
XJ, Wood J, Ross C, Sawyers CL, Whang YE (2000) Evi-
844 Am. J. Hum. Genet. 70:829–844, 2002
dence for regulation of PTEN tumor suppressor by a
membrane-localized multi-PDZ domain containing scaffold
protein MAG1-2. Proc Natl Acad Sci USA 97:4233–4238
Wu Y, Dowbenko D, Spencer S, Laura R, Lee J, Gu Q, Lasky
LA (2000) Interaction of the tumor suppressor PTEN/
MMAC with a PDZ domain of MAGI3, a novel membrane-
associated guanylate kinase. J Biol Chem 275:21477–21485
Yart A, Laffargue M, Mayeux P, Chretien S, Peres C, Tonks
N, Roche S, Payrastre B, Chap H, Raynal P (2001) A critical
role for phosphoinositide 3-kinase upstream of Gab1 and
SHP2 in the activation of ras and mitogen-activated protein
kinases by epidermal growth factor. J Biol Chem 276:
8856–8864
Zhou XP, Hampel H, Thiele H, Gorlin RJ, Hennekam R, Parisi
M, Winter RM, Eng C (2001a) Association of germline mu-
tation in the PTEN tumour suppressor gene and a subset of
Proteus sand Proteus-like syndromes. Lancet 358:210–211
Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng
C (2000) Germline and germline mosaic mutations associ-
ated with a Proteus-like syndrome of hemihypertrophy,
lower limb asymmetry, arterio-venous malformations and
lipomatosis. Hum Mol Genet 9:765–768
Zhou XP, Woodford-Richens K, Lehtonen R, Kurose K, Aldred
M,Hampel H, Launonen V, et al (2001b) Germlinemutations
in BMPR1A/ALK3 cause a subset of juvenile polyposis syn-
drome and of Cowden and Bannayan-Riley-Ruvalcaba syn-
dromes. Am J Hum Genet 69:704–711
Zori RT, Marsh DJ, Graham GE, Marliss EB, Eng C (1998)
Germline PTEN mutation in a family with Cowden syn-
drome and Bannayan-Riley-Ruvalcaba syndrome. Am J
Med Genet 80:399–402
